Site Map
This site map provides easy access to all pages of
Apidra.com for healthcare professionals. Learn about
Apidra® (insulin glulisine [rDNA origin] injection),
a rapid-acting insulin.
IMPORTANT SAFETY INFORMATION FOR APIDRA®
Apidra® is a rapid-acting human insulin analog indicated to improve
glycemic control in adults with type 2 diabetes or adults and children (4 years
and older) with type 1 diabetes. Apidra® is contraindicated during
episodes of hypoglycemia and in patients hypersensitive to Apidra®
or any of its excipients. Apidra® should normally be used in regimens
that include a longer-acting insulin.
Apidra® has a more rapid onset and shorter duration of action than
regular human insulin. When used as a mealtime insulin, the dose of Apidra®
should be given within 15 minutes before or within 20 minutes after starting a meal.
Glucose monitoring is essential for patients receiving insulin therapy. Any change
in insulin and/or regimen should be made cautiously, only under medical supervision,
and may require a change in dose. Concomitant oral antidiabetic treatment may need
to be adjusted. As with all insulin preparations, the time course of Apidra®
action may vary by individual or at different times in the same individual and depends
on injection site, blood supply, temperature, and level of physical activity.
Hypoglycemia is the most common adverse reaction of insulin therapy, including Apidra®.
The timing of hypoglycemia usually reflects the time-action profile of the administered
insulin formulations. Other adverse events associated with Apidra®
include hypokalemia, allergic reactions, injection site reactions, lipodystrophy,
pruritus, and rash. Less common, but potentially more serious or life-threatening,
is generalized allergy to insulin, including anaphylactic reactions.
Apidra® should not be
mixed with other insulins or with a diluent when used in the pump.
Please click here for full prescribing information for Apidra®
